Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.51 |
| ▸ | PHGDH | O43175 | 1/20 | 0.51 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.50 |
| ▸ | CKS1B | P61024 | 2/20 | 0.49 |
| ▸ | SKP1 | P63208 | 2/20 | 0.49 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.49 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.44 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.44 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2416196 | 0.91 | CYP11B2 (0.56) | GBA1ACHEPHGDHGPR119CKS1B | |
| SCHEMBL4558301 | 0.85 | BACE1 (0.59) | GBA1ACHEGPR119CKS1BSKP1 | |
| SCHEMBL17114986 | 0.84 | MAP4K4 (0.47) | GBA1PHGDHGPR119CYP11B2 | |
| SCHEMBL17114988 | 0.84 | MAP4K4 (0.47) | GBA1PHGDHGPR119CYP11B2 | |
| SCHEMBL5358513 | 0.81 | TRPV1 (0.50) | PHGDHP2RX7 | |
| SCHEMBL30368857 | 0.81 | GPR119 (0.53) | GPR119 | |
| SCHEMBL19297041 | 0.81 | GPR119 (0.53) | GPR119 | |
| SCHEMBL23360685 | 0.80 | DYRK1A (0.53) | ACHEGPR119 | |
| SCHEMBL29863072 | 0.80 | DYRK1A (0.53) | ACHEGPR119 | |
| SCHEMBL19297108 | 0.80 | GPR119 (0.49) | GBA1GPR119CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157463-B2 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | ELI LILLY AND COMPANY | 2004-03-25 | — | — | US | disclosed |
| EP-1368339-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002059107-A1 | SUBSTITUTED PIPERIDINES/PIPERAZINES AS MELANOCORTIN RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058936-A1 | Substituted piperidines/piperazines as melanocortin receptor agonists | MC1R, MC4R, MC5R | GBA1 2462/4885ACHE 4528/4885PHGDH 4335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.